NCT02250612 (SYLTAG) is a Phase 2 clinical trial of 1 drop of 0.375% SYL040012 (bamosiran) in Open Angle Glaucoma, sponsored by Sylentis, S.A..

Who is sponsoring NCT02250612?

NCT02250612 is sponsored by Sylentis, S.A..

What drugs are being tested in NCT02250612?

Interventions in NCT02250612: 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate.

What condition does NCT02250612 study?

NCT02250612 studies Open Angle Glaucoma, Ocular Hypertension.

Is NCT02250612 still recruiting?

NCT02250612 is currently completed. Last updated 11 December 2020.

Are results published for NCT02250612?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-12-11 · How we verify

NCT02250612: SYLTAG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension

Completed Phase 2 Results posted Last updated 11 December 2020

What this trial tests

Phase 2 trial testing 1 drop of 0.375% SYL040012 (bamosiran) in Open Angle Glaucoma in 184 participants. Completed in 1 January 2016.

Timeline

1 October 2014

Primary endpoint
1 August 2015

1 January 2016

Quick facts

Lead sponsor	Sylentis, S.A.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	184
Start date	1 October 2014
Primary completion	1 August 2015
Estimated completion	1 January 2016
Sites	21 locations across United States, Estonia, Germany, Spain

Drugs / interventions tested

1 drop of 0.375% SYL040012 (bamosiran) — full drug profile →
1 drop of 0.750% SYL040012 (bamosiran) — full drug profile →
1 drop of 1.125% SYL040012 (bamosiran) — full drug profile →
1 drop of 1.5% SYL040012 (bamosiran) — full drug profile →
1 drop of 0.5 % timolol maleate — full drug profile →

Conditions studied

Open Angle Glaucoma — all drugs for Open Angle Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Sylentis, S.A. — full company profile →

Who can join

18 and older, any sex, with Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
Time frame: Baseline and Day 28

Sponsor's own description

The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Noncoding RNA therapeutics - challenges and potential solutions.
Winkle M, El-Daly SM, Fabbri M, Calin GA. · · 2021 · cited 1123× · PMID 34145432 · DOI 10.1038/s41573-021-00219-z
Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
Advances in the delivery of RNA therapeutics: from concept to clinical reality.
Kaczmarek JC, Kowalski PS, Anderson DG. · · 2017 · cited 467× · PMID 28655327 · DOI 10.1186/s13073-017-0450-0
Preclinical and clinical development of siRNA-based therapeutics.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, et al · · 2015 · cited 331× · PMID 25666164 · DOI 10.1016/j.addr.2015.01.007
Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M, Aigner A. · · 2022 · cited 256× · PMID 35997897 · DOI 10.1007/s40259-022-00549-3
Paving the Road for RNA Therapeutics.
Dammes N, Peer D. · · 2020 · cited 159× · PMID 32893005 · DOI 10.1016/j.tips.2020.08.004
Therapeutic nucleic acids: current clinical status.
Sridharan K, Gogtay NJ. · · 2016 · cited 153× · PMID 27111518 · DOI 10.1111/bcp.12987
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, et al · · 2024 · cited 116× · PMID 38204162 · DOI 10.1016/j.ymthe.2024.01.005

Verify or expand the search:

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

NCT07228221 — Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma · Phase 4 · recruiting
NCT06883123 — Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · Phase 4 · recruiting
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT06246136 — Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery · NA · recruiting
NCT06061718 — Travoprost Intraocular Implant in Conjunction With Cataract Surgery · Phase 3 · active not recruiting

Other Sylentis, S.A. trials

Trials by the same sponsor.

NCT05637255 — A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-rel · Phase 2 · completed
NCT05310422 — Safety Study of Tivanisiran to Treat Dry Eye · Phase 3 · completed
NCT04819269 — Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome · Phase 3 · completed
NCT04782271 — Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops · Phase 1 · completed
NCT03108664 — HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02250612 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sylentis, S.A.
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02250612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing